cookunity glp-1 I Struggle to Find Time to Make Lunch, so I Tested Prepared Meal Delivery Food as Medicine: What Actually

From August to September of 2025, 486 new plaintiffs joined the group lawsuit against GLP-1 drug manufacturers, bringing the total to 2,676

Drawing from PSGs 2025 Trends in Drug Benefit Design Report, this webinar provides essential insights for benefits professionals navigating the complex landscape of GLP-1 coverage decisions

In a combined analysis of subcutaneous (SUSTAIN-6) and oral [PIONEER 6 (NCT02692716)] T2DM CVOTs, semaglutide consistently reduced MACE risk versus placebo across all eGFR and urinary albumin:creatinine ratio (UACR) subgroups [58] Additionally, semaglutide (SELECT) reduced MACE in participants with overweight/obesity and baseline CVD but no T2DM [48]

the agency also set deadlines by which compounding pharmacies would have to stop producing compounded GLP-1s under this rationale

doi:10.3390/jcm12010145 Academy of Nutrition and Dietetic: Nutrition Care Manual

Cardiovascular Outcomes Trials of Incretin-Based Therapies